The Case for a 6-Base Genome with Peter Fromen, CEO of Biomodal
Peter Fromen, CEO of Biomodal, explains the significance of 6-base genomics and distinguishing between mC and hmC for biological insights. He highlights Biomodal's colorectal cancer study, achieving 95% AUC for early detection, and frames hmC as a key indicator for early disease…